Skip to main content
Full access
Letter to the Editor
Published Online: 1 November 1999

Effectiveness of Olanzapine Treatment for Severe Obsessive-Compulsive Disorder

Publication: American Journal of Psychiatry
To the Editor: Although haloperidol and pimozide are commonly employed in treatment augmentation strategies for severe obsessive-compulsive disorder (OCD), the role of atypical neuroleptics is still unclear (1). Some reports suggest that risperidone and clozapine may induce OCD symptoms (2, 3); a patient with schizophrenia was written about recently whose obsessive-compulsive symptoms worsened with olanzapine treatment. However, we report on two severe cases of patients with OCD who dramatically improved after olanzapine was added to treatment with selective serotonin reuptake inhibitors for 3 months.
Mr. A, a 21-year-old man, had been suffering from OCD for 4 years, and his mother suffered from type II bipolar disorder. His main obsession was contamination, and his compulsions (washing rituals) occupied 8 hours a day, rendering him unfit for college or employment. Various treatments and augmentation strategies at appropriate doses had been ineffective. His Yale-Brown Obsessive Compulsive Scale total score at his first psychiatric interview was 40. He was taking sertraline, haloperidol, risperidone, and diazepam, but all psychiatric drugs were discontinued except sertraline (150 mg/day), and olanzapine (5 mg/day) titrated up to 10 mg/day over a week. After 15 days, Mr. A reported significantly lessened anxiety and, after 1 month, significantly lessened obsessive-compulsive symptoms. By the third month, his symptoms were occurring for only minutes each week (Yale-Brown Obsessive Compulsive Scale total score of 6). At this point, he decided to work and to attend evening school.
Ms. B, a 29-year-old woman, suffered from OCD (with postpartum onset 4 years previously) and had a father who suffered from OCD and alcohol abuse and a mother with type II bipolar disorder. She had order and symmetry obsessions and compulsions that consisted of repeated checking, counting rituals, and washing objects in her room, where she spent 7 hours a day. She became anxious when anyone entered her room and interfered with her rituals. Ms. B was unable to work; her familial and social relationships were severely impaired. Of the various treatments, only fluvoxamine (300 mg/day) led to temporary improvement. Ms. B was given an added 5 mg/day of olanzapine, titrated up to 15 mg over 2 weeks. After 20 days, the dysphoria and irritability that were associated with her compulsions had lessened notably, and over 3 months, her Yale-Brown Obsessive Compulsive Scale total score had decreased progressively from 40 to 8. Her compulsions then occupied only 10 minutes a day. She was undergoing cognitive behavioral therapy and intended to work.
These case reports suggest that olanzapine may help severe, otherwise untreatable patients with OCD and might help resolve frequent diagnostic dilemmas regarding patients with schizophrenia with obsessive-compulsive symptoms and patients with psychotic features with OCD. It is interesting that both patients’ mothers were suffering from type II bipolar disorder: this observation, supported by similar findings in other patients, suggests that having a family history of bipolar disorder might predict a good response to olanza­pine. Further assessment of the potential benefits of olanza­pine treatment in a defined subgroup of treatment-resistant patients with OCD is warranted.

References

1.
Baker RW, Bermazonn PC, Wirshing DA, Chengappa KNR: Obsessions, compulsions, clozapine and risperidone. Central Nervous System Spectrums 1997; 2:6–36
2.
Patel B, Tandon R: Development of obsessive-compulsive symptoms during clozapine treatment (letter). Am J Psychiatry 1993; 150:836
3.
Morrison D, Clark D, Goldfarb E, McCoy L: Worsening of obsessive-compulsive symptoms following treatment with olanzapine (letter). Am J Psychiatry 1998; 155:855

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 1834-a - 1835

History

Published online: 1 November 1999
Published in print: November 1999

Authors

Affiliations

DONATELIA MARAZZITI, M.D.
Pisa, Italy
STEFANO PALLANTI, M.D.
Firenze, Italy

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share